- Home
- MGNX vs BW Comparison
MGNX vs BW Comparison
Compare MGNX & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- BW
- Stock Information
- Founded
- MGNX 2000
- BW 1867
- Country
- MGNX United States
- BW United States
- Employees
- MGNX N/A
- BW N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- BW Building Products
- Sector
- MGNX Health Care
- BW Industrials
- Exchange
- MGNX Nasdaq
- BW Nasdaq
- Market Cap
- MGNX 151.9M
- BW 182.0M
- IPO Year
- MGNX 2013
- BW N/A
- Fundamental
- Price
- MGNX $2.20
- BW $0.96
- Analyst Decision
- MGNX Hold
- BW Strong Buy
- Analyst Count
- MGNX 10
- BW 3
- Target Price
- MGNX $7.17
- BW $4.50
- AVG Volume (30 Days)
- MGNX 551.0K
- BW 859.6K
- Earning Date
- MGNX 05-08-2025
- BW 05-08-2025
- Dividend Yield
- MGNX N/A
- BW N/A
- EPS Growth
- MGNX N/A
- BW N/A
- EPS
- MGNX N/A
- BW N/A
- Revenue
- MGNX $141,329,000.00
- BW $878,224,000.00
- Revenue This Year
- MGNX $177.84
- BW N/A
- Revenue Next Year
- MGNX N/A
- BW N/A
- P/E Ratio
- MGNX N/A
- BW N/A
- Revenue Growth
- MGNX 16.68
- BW N/A
- 52 Week Low
- MGNX $2.15
- BW $0.75
- 52 Week High
- MGNX $19.54
- BW $2.99
- Technical
- Relative Strength Index (RSI)
- MGNX 35.93
- BW 32.70
- Support Level
- MGNX $2.16
- BW $0.96
- Resistance Level
- MGNX $2.49
- BW $1.10
- Average True Range (ATR)
- MGNX 0.17
- BW 0.08
- MACD
- MGNX -0.00
- BW 0.00
- Stochastic Oscillator
- MGNX 7.87
- BW 6.41
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.